TICKERNERD
Menu
YARWYARWHealthcare · Biotechnology

YARW Stock Forecast: Yarrow Bioscience, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$34
−4.08% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$0.00
Ticker Nerd rank
34 / 100
Median analyst target
—
Analysts covering
2
Total return, dividends reinvested
1W
+17.6%
1M
+41.9%
YTD
+66.3%
1Y
+173.3%
From 52W high
−4.1%
From 52W low
+236.1%
$10
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

YARW stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Yarrow Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Growth
70
Volatility
48
Quality
44
Accruals
44
Momentum
40
Value
32
Issuance
32
Revisions
28

Size (86): Smaller than most of the companies we track.

Revisions (28): Analysts have, on balance, been cutting their forecasts.

The rank is the raw material. Whether the rules would actually own Yarrow Bioscience, Inc. — and when they’d sell — is the membership.

Wall Street

YARW stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on YARW, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26YARW

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026BTIGInitiatesBuy$58
28 July 2026TD CowenInitiatesBuy—
30 July 2025HC Wainwright & Co.DowngradeNeutral—
25 Apr 2025HC Wainwright & Co.MaintainsBuy—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
6 Jan 2025HC Wainwright & Co.ReiteratesBuy—
23 Dec 2024HC Wainwright & Co.ReiteratesBuy—
18 Nov 2024BTIGInitiatesBuy—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Sept 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
29 Feb 2024HC Wainwright & Co.ReiteratesBuy—
30 Oct 2023HC Wainwright & Co.MaintainsBuy—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

YARW analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Yarrow Bioscience, Inc. (YARW) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.7×

Cheaper than 70% of US stocks

Price / sales
42.0×

Cheaper than 6% of US stocks

Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
−57.4%

Higher than 4% of US stocks

Earnings growth (YoY)
−57.4%

Higher than 8% of US stocks

Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−63.2%

Higher than 18% of US stocks

Return on assets
−37.0%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

YARW vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
YARWYarrow Bioscience, Inc.$0.00
34
ESLAEstrella Immunopharma, Inc.$30.0M
19
SERSerina Therapeutics, Inc.$29.8M
15
BCTXBriaCell Therapeutics Corp.$29.6M
7
CALCCalciMedica, Inc.$30.7M
36
KYNBKyntra Bio, Inc.$27.2M
67
LTRNLantern Pharma, Inc.$33.6M
68
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. YARW appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest YARW news & analysis

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease

Business Wire · 27 July 2026positive

Yarrow Bioscience announced the completion of its merger with VYNE Therapeutics and the initiation of dosing in a Phase 2a/2b trial of YB-101 for Graves' disease and thyroid eye disease, along with private financings totaling approximately $200 million.

Why it matters — VYNE watchers would care because the company has been merged into Yarrow Bioscience, which now has a funded clinical program underway for a potential first-in-class treatment for autoimmune thyroid diseases.

FAQ

Frequently asked questions about YARW stock

Is YARW stock a buy right now?

Of the 2 analysts covering Yarrow Bioscience, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Yarrow Bioscience, Inc. 34 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank YARW?

As at 1 Aug 2026, Yarrow Bioscience, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

What is the YARW stock forecast for 2030?

No analyst covering Yarrow Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YARW are extrapolating price history, which says nothing about the business.

How has YARW stock performed over the past year?

Yarrow Bioscience, Inc. returned +173.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Yarrow Bioscience, Inc. do?

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing biotherapeutic treatments for autoimmune thyroid diseases.

What is the latest news on YARW?

The most recent item we track (Business Wire, 27 July 2026): "Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease". Yarrow Bioscience announced the completion of its merger with VYNE Therapeutics and the initiation of dosing in a Phase 2a/2b trial of YB-101 for Graves' disease and thyroid eye disease, along with private financings totaling approximately $200 million.

Company

About Yarrow Bioscience, Inc.

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing biotherapeutic treatments for autoimmune thyroid diseases. The company’s core activity centers on advancing YB-101, a humanized monoclonal antibody that targets the thyroid-stimulating hormone receptor (TSHR), designed for the treatment of Graves’ disease and thyroid eye disease. By concentrating on this receptor-driven mechanism, Yarrow Bioscience aims to address conditions characterized by overactive thyroid function and associated orbital inflammation. The company operates with a single reportable segment dedicated to research and development for these thyroid-related programs, reflecting a highly specialized therapeutic focus. Incorporated in 2025 and headquartered in New York, New York, Yarrow Bioscience works within the broader pharmaceuticals and biotechnology ecosystem, collaborating with partners and leveraging clinical research to progress its pipeline. Within the health care sector, it serves a niche but clinically important area of endocrine and immune-mediated disorders, contributing potential options for patients with significant unmet medical needs in autoimmune thyroid disease management.

CEO Ms. Rebecca Velez Frey Pharm.D. · United States · https://www.yarrowbioscience.com